# STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

> **NCT02586038** · PHASE2 · COMPLETED · sponsor: **Mario Boccadoro** · enrollment: 175 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MLN9708
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT02586038
- **Lead sponsor:** Mario Boccadoro
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2023-10
- **Final completion:** 2023-12
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586038, "STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02586038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*